N,N’-去乙烯-N,N’-二甲酰基左氧氟沙星 | 151377-74-1

• 物质功能分类: 分析化学 - 对照品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: N,N’-去乙烯-N,N’-二甲酰基左氧氟沙星
• 中文别名: 左氧氟沙星去乙烯乙二醛杂质
• 英文名称: S-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(1,4-diformyl-1,4-diazapentyl)-7-oxo-7H-pyrido-<1,2,3-de><1,4>benzoxazine-6-carboxylic acid
• 英文别名: N,N'-Desethylene-N,N'-diformyl Levofloxacin；(2S)-7-fluoro-6-[formyl-[2-[formyl(methyl)amino]ethyl]amino]-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
• CAS: 151377-74-1
• 化学式: C₁₈H₁₈FN₃O₆
• 分子量: 391.356
• InChiKey: HTOKHJLTWLBPPN-JTQLQIEISA-N

物化性质

• 熔点：
  179-181°C
• 沸点：
  708.6±60.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（非常轻微，加热）

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

制备方法与用途

简介

左氧氟沙星（levofloxacin）是氧氟沙星的左旋体，以其广谱且强大的抗菌作用著称。其原研厂家为日本第一株式会社，并于1993年首先在日本上市。剂型包括片剂，现已在美国、英国及中国等多国上市。目前国内市场上有片剂、注射剂和水针等多种剂型的左氧氟沙星制剂。左氧氟沙星去乙烯乙二醛杂质则是该药物的一种杂质。

用途

左氧氟沙星去乙烯乙二醛杂质可用作医药对照品。

反应信息

• 作为产物：
  描述：

  左氧氟沙星 以 水 为溶剂， 反应 16.0h， 生成 S-(-)-9-fluoro-2,3-dihydro-3-methyl-10-amino-7-oxo-7H-pyrido-<1,2,3-de><1,4>benzoxazine-6-carboxylic acid 、 左氧氟沙星USP杂质B 、 9-氟-3-甲基-7-氧代-10-(1-哌嗪基)-2,3-二氢-7H-[1,4]恶嗪并[2,3,4-Ij]喹啉-6-羧酸 、 S-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-formyl-1,4-diazapentyl)-7-oxo-7H-pyrido-<1,2,3-de><1,4>benzoxazine-6-carboxylic acid 、 S-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(1-formyl-1,4-diazapentyl)-7-oxo-7H-pyrido-<1,2,3-de><1,4>benzoxazine-6-carboxylic acid 、 N,N’-去乙烯-N,N’-二甲酰基左氧氟沙星 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Yoshida; Sato; Moroi, Arzneimittel-Forschung/Drug Research, 1993, vol. 43, # 5, p. 601 - 606

  摘要：

  DOI：

文献信息

• Visible light-driven photocatalytic degradation of organic pollutants by a novel Ag3VO4/Ag2CO3 p–n heterojunction photocatalyst: Mechanistic insight and degradation pathways
  作者：Haibo Sun、Pufeng Qin、Zhibin Wu、Chanjuan Liao、Jiayin Guo、Shuai Luo、Youzheng Chai

  DOI：10.1016/j.jallcom.2020.155211

  日期：2020.9

  In the field of photocatalysis, the construction of a heterojunction system with efficient charge separation at the interface and charge transfer to increase the photocatalyst performance has gained considerable attention. In this study, the Ag3VO4/Ag(2)CO(3 )p-n heterojunction is first synthesized using a simple coprecipitation method. The composite photocatalyst with a p-n heterojunction has a strong internal electric field, and its strong driving force can effectively solve the problem of low separation and migration efficiency of photogenerated electron-hole pairs. The optimized Ag3VO4/Ag2CO3 composite can effectively degrade organic pollutants (rhodamine b (RhB), methylene blue (MB), levofloxacin (LVF), and tetracycline). More specifically, the Ag3VO4/Ag2CO3 photocatalyst with a 1:2 mass ratio (VC-12) can remove 97.8% and 82% of RhB and LVF within 30 and 60 min, respectively. The LVF degradation rate by VC-12 under visible light irradiation is more than 12.8 and 21.51 times higher than those of pure Ag3VO4 and Ag2CO3, respectively. The excellent photocatalytic activity of the Ag3VO4/Ag2CO3 hybrid system is mainly attributed to the internal electric field that forms in the Ag3VO4/Ag2CO3 p-n heterojunction system, the photogenerated electron hole pairs that separate and facilely migrate, and the specific surface area of VC-12 that is larger than that of the monomer. In addition, the degradation efficiency of VC-12 did not decline significantly after four cycles. In this study, the photocatalytic mechanism for Ag3VO4/Ag2CO3 photocatalysts is explored in detail based on the energy band analysis results, trapping experiment results, and electron spin resonance spectra. Finally, the LVF degradation products are analyzed by liquid chromatography-mass spectrometry, and the potential LVF degradation pathway is identified. The experiments performed in this research therefore lead to new motivation for the design and synthesis of highly efficient and widely applicable photocatalysts for environmental purification. (C) 2020 Elsevier B.V. All rights reserved.
• Yoshida; Sato; Moroi, Arzneimittel-Forschung/Drug Research, 1993, vol. 43, # 5, p. 601 - 606
  作者：Yoshida、Sato、Moroi

  DOI：——

  日期：——